Idioma:

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, Robert J ; Tannir, Nizar M ; McDermott, David F ; Arén Frontera, Osvaldo ; Melichar, Bohuslav ; Choueiri, Toni K ; Plimack, Elizabeth R ; Barthélémy, Philippe ; Porta, Camillo ; George, Saby ; Powles, Thomas ; Donskov, Frede ; Neiman, Victoria ; Kollmannsberger, Christian K ; Salman, Pamela ; Gurney, Howard ; Hawkins, Robert ; Ravaud, Alain ; Grimm, Marc-Oliver ; Bracarda, Sergio ; Barrios, Carlos H ; Tomita, Yoshihiko ; Castellano, Daniel ; Rini, Brian I ; Chen, Allen C ; Mekan, Sabeen ; McHenry, M. Brent ; Wind-Rotolo, Megan ; Doan, Justin ; Sharma, Padmanee ; Hammers, Hans J ; Escudier, Bernard

The New England journal of medicine, 2018-04, Vol.378 (14), p.1277-1290 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Autor: Motzer, Robert J ; Tannir, Nizar M ; McDermott, David F ; Arén Frontera, Osvaldo ; Melichar, Bohuslav ; Choueiri, Toni K ; Plimack, Elizabeth R ; Barthélémy, Philippe ; Porta, Camillo ; George, Saby ; Powles, Thomas ; Donskov, Frede ; Neiman, Victoria ; Kollmannsberger, Christian K ; Salman, Pamela ; Gurney, Howard ; Hawkins, Robert ; Ravaud, Alain ; Grimm, Marc-Oliver ; Bracarda, Sergio ; Barrios, Carlos H ; Tomita, Yoshihiko ; Castellano, Daniel ; Rini, Brian I ; Chen, Allen C ; Mekan, Sabeen ; McHenry, M. Brent ; Wind-Rotolo, Megan ; Doan, Justin ; Sharma, Padmanee ; Hammers, Hans J ; Escudier, Bernard
Assuntos: Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Body weight ; Cancer ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - mortality ; Clear cell-type renal cell carcinoma ; Disease-Free Survival ; Hospitals ; Humans ; Immunotherapy ; Indoles - administration & dosage ; Indoles - adverse effects ; Inhibitor drugs ; Ipilimumab - administration & dosage ; Ipilimumab - adverse effects ; Kidney cancer ; Kidney Neoplasms - drug therapy ; Male ; Medical prognosis ; Medical research ; Melanoma ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Neutrophils ; Nivolumab ; Patients ; Pyrroles - administration & dosage ; Pyrroles - adverse effects ; Quality of Life ; Response rates ; Risk ; Sunitinib ; Survival Analysis ; Survival Rate ; Targeted cancer therapy
É parte de: The New England journal of medicine, 2018-04, Vol.378 (14), p.1277-1290
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
A complete list of investigators in the CheckMate 214 trial is provided in the Supplementary Appendix, available at NEJM.org.
Drs. Sharma, Hammers, and Escudier contributed equally to this article.
The authors’ full names, academic degrees, and affiliations are listed in the Appendix.
Descrição: In a randomized trial involving previously untreated patients with metastatic intermediate- or poor-risk renal-cell cancer, nivolumab plus ipilimumab was associated with higher response rates, longer overall survival, and greater improvement in quality of life than sunitinib.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 18 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.